NO992296L - FremgangsmÕte for disubstituerte pyridiner - Google Patents

FremgangsmÕte for disubstituerte pyridiner

Info

Publication number
NO992296L
NO992296L NO992296A NO992296A NO992296L NO 992296 L NO992296 L NO 992296L NO 992296 A NO992296 A NO 992296A NO 992296 A NO992296 A NO 992296A NO 992296 L NO992296 L NO 992296L
Authority
NO
Norway
Prior art keywords
formula
amino
nitro
processes
preparation
Prior art date
Application number
NO992296A
Other languages
English (en)
Norwegian (no)
Other versions
NO992296D0 (no
Inventor
Keith Michael Devries
Robert Lee Dow
Stephen Wayne Wright
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of NO992296D0 publication Critical patent/NO992296D0/no
Publication of NO992296L publication Critical patent/NO992296L/no

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72Nitrogen atoms
    • C07D213/73Unsubstituted amino or imino radicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72Nitrogen atoms
    • C07D213/75Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00Technologies relating to chemical industry
    • Y02P20/50Improvements relating to the production of bulk chemicals
    • Y02P20/55Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
NO992296A 1996-11-14 1999-05-12 FremgangsmÕte for disubstituerte pyridiner NO992296L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US3088096P 1996-11-14 1996-11-14
PCT/IB1997/001367 WO1998021184A1 (en) 1996-11-14 1997-11-03 Process for substituted pyridines

Publications (2)

Publication Number Publication Date
NO992296D0 NO992296D0 (no) 1999-05-12
NO992296L true NO992296L (no) 1999-05-12

Family

ID=21856496

Family Applications (1)

Application Number Title Priority Date Filing Date
NO992296A NO992296L (no) 1996-11-14 1999-05-12 FremgangsmÕte for disubstituerte pyridiner

Country Status (32)

Country Link
US (1) US6291489B1 (US06291489-20010918-C00067.png)
EP (1) EP0938476B1 (US06291489-20010918-C00067.png)
JP (1) JP3510635B2 (US06291489-20010918-C00067.png)
KR (1) KR20000053314A (US06291489-20010918-C00067.png)
CN (1) CN1237160A (US06291489-20010918-C00067.png)
AP (1) AP805A (US06291489-20010918-C00067.png)
AR (1) AR010584A1 (US06291489-20010918-C00067.png)
AT (1) ATE319687T1 (US06291489-20010918-C00067.png)
AU (1) AU4634697A (US06291489-20010918-C00067.png)
BG (1) BG103393A (US06291489-20010918-C00067.png)
BR (1) BR9712951A (US06291489-20010918-C00067.png)
CA (1) CA2270386C (US06291489-20010918-C00067.png)
CO (1) CO4930261A1 (US06291489-20010918-C00067.png)
DE (1) DE69735433D1 (US06291489-20010918-C00067.png)
EA (1) EA199900375A1 (US06291489-20010918-C00067.png)
GT (1) GT199700118A (US06291489-20010918-C00067.png)
HR (1) HRP970612A2 (US06291489-20010918-C00067.png)
ID (1) ID18898A (US06291489-20010918-C00067.png)
IL (1) IL129688A0 (US06291489-20010918-C00067.png)
IS (1) IS5029A (US06291489-20010918-C00067.png)
MA (1) MA24401A1 (US06291489-20010918-C00067.png)
MY (1) MY132507A (US06291489-20010918-C00067.png)
NO (1) NO992296L (US06291489-20010918-C00067.png)
OA (1) OA11044A (US06291489-20010918-C00067.png)
PA (1) PA8441401A1 (US06291489-20010918-C00067.png)
PE (1) PE10299A1 (US06291489-20010918-C00067.png)
TN (1) TNSN97172A1 (US06291489-20010918-C00067.png)
TR (1) TR199901063T2 (US06291489-20010918-C00067.png)
UY (1) UY24774A1 (US06291489-20010918-C00067.png)
WO (1) WO1998021184A1 (US06291489-20010918-C00067.png)
YU (1) YU22099A (US06291489-20010918-C00067.png)
ZA (1) ZA9710186B (US06291489-20010918-C00067.png)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ID26299A (id) * 1998-04-08 2000-12-14 Novartis Ag Herbisida baru
US6090942A (en) * 1998-10-15 2000-07-18 Pfizer Inc. Process and intermediates for a β3 -adrenergic receptor agonist
CA2362070A1 (en) * 1999-02-16 2000-08-24 Masaru Mitsuda Substituted acetylpyridine derivatives and process for the preparation of intermediates for optically active .beta.3 agonist by the use of the same
US6455734B1 (en) * 2000-08-09 2002-09-24 Magnesium Diagnostics, Inc. Antagonists of the magnesium binding defect as therapeutic agents and methods for treatment of abnormal physiological states
DE60015036T2 (de) * 1999-07-23 2006-03-02 Pfizer Products Inc., Groton Zwischenprodukte und ein Verfahren zur Herstellung von beta3-Adrenergischer Rezeptor-Agoniste
EP1454899A1 (en) * 2001-10-17 2004-09-08 Kaneka Corporation Process for preparation of (s)-alpha-halome thylpyridine methanol derivatives
CA2471646A1 (en) 2002-02-27 2003-09-04 Yong Tao Processes and intermediates useful in preparing .beta.3-adrenergic receptor agonists
AU2003209527A1 (en) 2002-02-27 2003-09-09 Pfizer Products Inc. Crystal forms of (r)-2-(2-(4-oxazol-4-yl-phenoxy)-ethylamino)-1-pyridin-3-yl-ethanol
US6864268B2 (en) 2002-02-27 2005-03-08 Pfizer Inc. β3 adrenergic receptor agonists
EP1424079A1 (en) * 2002-11-27 2004-06-02 Boehringer Ingelheim International GmbH Combination of a beta-3-receptor agonist and of a reuptake inhibitor of serotonin and/or norepinephrine
RU2313524C2 (ru) 2003-05-09 2007-12-27 Ф.Хоффманн-Ля Рош Аг МИТИЛИНДОЛЫ И МЕТИЛПИРРОЛОПИРИДИНЫ, ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ, ОБЛАДАЮЩАЯ АКТИВНОСТЬЮ α-1-АДРЕНЕРГИЧЕСКИХ АГОНИСТОВ
US7977359B2 (en) 2005-11-04 2011-07-12 Amira Pharmaceuticals, Inc. 5-lipdxygenase-activating protein (FLAP) inhibitors
GB2431927B (en) 2005-11-04 2010-03-17 Amira Pharmaceuticals Inc 5-Lipoxygenase-activating protein (FLAP) inhibitors
US8399666B2 (en) 2005-11-04 2013-03-19 Panmira Pharmaceuticals, Llc 5-lipoxygenase-activating protein (FLAP) inhibitors
EA019819B1 (ru) 2008-05-23 2014-06-30 ПАНМИРА ФАРМАСЬЮТИКАЛЗ, ЭлЭлСи Кристаллическая полиморфная форма с ингибитора белка, активирующего 5-липоксигеназу, фармацевтическая композиция на ее основе и применение в лечении

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4358455A (en) 1980-12-23 1982-11-09 Merck & Co., Inc. Aralkylamindethanol heterocyclic compounds
US5019578A (en) 1987-11-27 1991-05-28 Merck & Co., Inc. β-adrenergic agonists
WO1994029290A1 (en) * 1993-06-14 1994-12-22 Pfizer Inc. Secondary amines as antidiabetic and antiobesity agents
IL113410A (en) * 1994-04-26 1999-11-30 Merck & Co Inc Substituted sulfonamides having an asymmetric center and pharmaceutical compositions containing them
WO1996035670A1 (en) 1995-05-10 1996-11-14 Pfizer Inc. β-ADRENERGIC AGONISTS
JPH11504649A (ja) * 1995-05-10 1999-04-27 ファイザー・インコーポレーテッド β−アドレナリン作働性アゴニスト

Also Published As

Publication number Publication date
OA11044A (en) 2002-02-20
EP0938476B1 (en) 2006-03-08
AU4634697A (en) 1998-06-03
MA24401A1 (fr) 1998-07-01
YU22099A (sh) 2001-09-28
ATE319687T1 (de) 2006-03-15
KR20000053314A (ko) 2000-08-25
AP805A (en) 2000-01-28
CO4930261A1 (es) 2000-06-27
IS5029A (is) 1999-04-16
NO992296D0 (no) 1999-05-12
CA2270386C (en) 2004-08-03
JP2000504347A (ja) 2000-04-11
JP3510635B2 (ja) 2004-03-29
CA2270386A1 (en) 1998-05-22
HRP970612A2 (en) 1998-08-31
IL129688A0 (en) 2000-02-29
US6291489B1 (en) 2001-09-18
AP9701147A0 (en) 1998-01-31
CN1237160A (zh) 1999-12-01
TR199901063T2 (xx) 1999-08-23
MY132507A (en) 2007-10-31
PE10299A1 (es) 1999-02-10
TNSN97172A1 (fr) 2005-03-15
GT199700118A (es) 1999-05-05
ZA9710186B (en) 1999-05-12
BR9712951A (pt) 1999-12-07
DE69735433D1 (de) 2006-05-04
EA199900375A1 (ru) 1999-12-29
EP0938476A1 (en) 1999-09-01
UY24774A1 (es) 1998-05-05
WO1998021184A1 (en) 1998-05-22
AR010584A1 (es) 2000-06-28
ID18898A (id) 1998-05-20
PA8441401A1 (es) 2000-05-24
BG103393A (en) 2000-07-31

Similar Documents

Publication Publication Date Title
NO992296L (no) FremgangsmÕte for disubstituerte pyridiner
ATE269312T1 (de) N-(amidinophenyl)-n'-(subst.)-3h-2,4- benzodiazepin-3-on derivative als faktor xa inhibitoren
NO955047L (no) Sekundære aminer som antidiabetiske og antifedme-midler
YU34896A (sh) Supstituisani n-(indol-2-karbonil)-glicinamidi, njihovi intermedijeri i farmaceutske kompozicije
MX9701893A (es) Nuevos inhibidores de la prostaglandinsintasa.
DK0946546T3 (da) Pyridin-2-yl-methylaminderivater, fremgangsmåde til fremstilling heraf og anvendelse heraf som lægemidler
UA6306A1 (uk) Спосіб одержання метиловіх ефірів 2-гетаріл-3-метоксіакрілової кислоти
DK0715628T3 (da) Substituerede azaindolyliden-forbindelser og fremgangsmåde til fremstilling deraf
MY107740A (en) Saccharin derivatives useful as proteolytic enzyme inhibitors and compositions and method of use thereof
BR9509665A (pt) Composto composições e métodos
DE69433984D1 (de) Arylpiperazinderivate von indol als liganden der rezeptoren 5 ht1-like, 5 ht1b und 5 ht1d
NO985335L (no) 2,4-Diaminopyrimidinderivater
NO952205L (no) Heterocykliske karbamater, fremgangsmåte for fremstilling derav og medikamenter
NO924988D0 (no) Tiazolidinforbindelser som inneholder kinongrupper, og fremgangsmaate til fremstilling derav
DK0601486T3 (da) Cis-epoxidderivater, der er egnede som irreversible HIV-proteaseinhibitorer, og fremgangsmåde og mellemprodukter til deres
DK362584A (da) 1-substituerede 4-hydroxymethylpyrrolidinoner, fremgangsmaade til fremstilling deraf, farmaceutiske praeparater og mellemprodukter
DE60227421D1 (de) Rmazeutische zusammensetzung und verwendung davon
DK0552758T3 (da) N-5-Beskyttede 2,5-diamino-4,6-dichlorpyrimidiner og fremgangsmåde til deres fremstilling
EA200401099A1 (ru) Производные гетероциклического амида
DE69316392D1 (de) Azanoradamantane
AR003964A1 (es) Nuevos azepanos y homologos de su anillo, compuestos de partida para su preparacion, procedimiento para la elaboracion de dichos azepanos y sushomologos de anillo y composiciones farmaceuticas que los contienen.
DK0475352T3 (da) 3-(1H-Indazol-3-yl)-4-pyridinaminer, fremgangsmåde og mellemprodukter til deres fremstilling og deres anvendelse som lægemidler
DK0483633T3 (da) 8-Azabicyclo 3,2,1 octylalkylthiazoliddinoner, fremgangsmåde til deres fremstilling og deres anvendelse som lægemidler.
BR0010488A (pt) Tienocicloalqu(en)ilamino-1,3,5-triazinas substituìdas
NO306714B1 (no) Krystallinsk, polymorf form av (S,S,S)-N-(1-[2-karboksy-3-(N2-mesyllysylamino)propyl]-1-cyklopentylkarbonyl)-tyrosin

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application